Clinical Trials on Steroid Refractory Acute Graft Versus Host Disease

Total 3302 results

AltruBio Inc.

Completed

Neihulizumab (ALTB-168) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease

Steroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host Disease

United States
medac GmbH

Recruiting

Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease (BALDER)

Steroid-refractory Acute Graft-versus-host Disease

Germany, Spain, France, Poland
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802) (1802)

Steroid-Refractory Acute Graft Versus Host Disease

United States
medac GmbH

Recruiting

Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (IDUNN)

Steroid-refractory Acute Graft-versus-host Disease

Spain, Germany, France, Poland, Sweden
Xenikos
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Terminated

A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) (2002)

Steroid-Refractory Acute Graft Versus Host Disease

United States, Belgium, Croatia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Nanfang Hospital of Southern Medical University

Unknown

Efficacy and Safety of FMT Capsule Treating Steroid-refractory GI-aGvHD

Steroid-refractory Gastrointestinal Acute Graft Versus Host Disease

China
Anhui Provincial Hospital

Recruiting

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)

China
Hannah Choe, MD
National Cancer Institute (NCI); Plexxikon

Terminated

Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD

Acute Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
MaaT Pharma

Recruiting

MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients (ARES)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

Spain, France, Germany, Austria, Belgium, Italy
University of Liege

Terminated

Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)

Chronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host Disease

Belgium
MaaT Pharma

Available

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease (ATLAS)

Acute Graft Versus Host Disease in Intestine | Steroid Refractory GVHD

France
Nationwide Children's Hospital

Terminated

Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Graft Versus Host Disease | Acute GVH Disease | Steroid Refractory GVHD

United States
Columbia University
Incyte Corporation

Terminated

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Graft Vs Host Disease | Steroid Refractory GVHD

United States
Therakos, Inc., a Mallinckrodt Company

Terminated

Methoxsalen and Extracorporeal Photopheresis (ECP) for the Treatment of Pediatric Participants With Steroid Refractory Acute Graft Versus Host Disease

Steroid Refractory Acute Graft Versus Host Disease

United States, Spain, France, Austria, Germany, Hungary, Italy, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

Hematopoietic and Lymphoid Cell Neoplasm | Steroid Refractory Graft Versus Host Disease

United States
ReAlta Life Sciences, Inc.

Not yet recruiting

Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease (AURORA)

Steroid Refractory GVHD
ElsaLys Biotech

Available

Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

Steroid Resistant Acute Graft Versus Host Disease

France
The Korean Society of Hematopoietic Stem Cell Transplantation
Hoffmann-La Roche

Unknown

Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease

Steroid-Refractory Chronic GVHD

Korea, Republic of
Jonsson Comprehensive Cancer Center

Withdrawn

Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Acute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease

United States
Impatients N.V. trading as myTomorrows
Kamada, Ltd.

No longer available

Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)

Alpha 1-Antitrypsin Deficiency | Graft Vs Host Disease | Graft-versus-host-disease | Acute-graft-versus-host Disease | Steroid Refractory Acute Graft Versus Host Disease | Alpha-1 Proteinase Inhibitor | Alpha-1 Protease Inhibitor Deficiency | Acute Graft-Versus-Host Reaction Following Bone Marrow...
Novartis Pharmaceuticals

Available

Managed Access Programs for INC424, Ruxolitinib

Primary Myelofibrosis (PMF) | Polycythemia Vera (PV) | Post Polycythemia Myelofibrosis (PPV MF) | Thrombocythemia Myelofibrosis (PET-MF) | Severe/Very Severe COVID-19 Illness | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease...
Mesoblast, Inc.
Quintiles, Inc.

Completed

Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD

Grade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease

United States
Jazz Pharmaceuticals

Completed

An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)

Acute-graft-versus-host Disease | Graft-versus-host Disease

United States, Belgium, United Kingdom, Greece, Germany, Spain, France, Italy, Austria, Canada, Bulgaria, Croatia, Poland, Portugal
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Leflunomide in Treating Patients With Steroid Dependent Chronic Graft Versus Host Disease

Chronic Graft Versus Host Disease | Steroid Refractory Graft Versus Host Disease

United States
Shenzhen Xbiome Biotech Co., Ltd.
Beijing Improve-Quality Tech.Co., Ltd.

Recruiting

Safety and Tolerability of FMT Capsules in Healthy Volunteers

Acute-graft-versus-host Disease

China
Cytopeutics Sdn. Bhd.
Universiti Tunku Abdul Rahman

Active, not recruiting

UCMSCs as Front-line Approach of Treatment for Patients With aGVHD (GVHD Cyto-MSC)

Acute-graft-versus-host Disease

Malaysia
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
Incyte Corporation

Completed

Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects

Acute Graft-versus-host Disease

Japan
Central Hospital, Nancy, France

Unknown

A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease (PCE-aGVHD)

Acute-graft-versus-host Disease
Mallinckrodt
PRA Health Sciences

Terminated

Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Acute Graft Versus-Host Disease

Acute Graft-versus-Host Disease

United States, Canada, Germany, United Kingdom, Australia, Austria, Belgium, Italy, France, Netherlands, Switzerland
moshe yeshurun

Unknown

Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease

Acute-graft-versus-host Disease

Israel
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaborators

Unknown

MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD

Acute Graft-versus-host Disease

China
Nanfang Hospital of Southern Medical University
Peking University People's Hospital; Sun Yat-sen University; Guangzhou First... and other collaborators

Unknown

Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease

Acute Graft-versus-host Disease

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Not yet recruiting

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Acute Graft-Versus-Host Disease

China
ASC Therapeutics

Not yet recruiting

ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Acute-graft-versus-host Disease
The First Affiliated Hospital of Soochow University

Recruiting

Fecal Microbiota Transplantation in Gut aGVHD Treated

Acute-graft-versus-host Disease

China
Genentech, Inc.

Completed

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Acute Graft-versus-host Disease

United States
Genentech, Inc.

Terminated

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

Acute Graft-versus-host Disease

United States, Canada
Masonic Cancer Center, University of Minnesota

Recruiting

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Acute-graft-versus-host Disease

United States
Universitätsklinikum Hamburg-Eppendorf
Mallinckrodt; University Medical Center Regensburg; Arbeitskreis Klinische Forschung...

Recruiting

Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease

Acute-graft-versus-host Disease

Germany, Austria
Nanfang Hospital, Southern Medical University

Active, not recruiting

Donor Neutrophil Subsets to Predict the Risk of aGVHD

Acute Graft-versus-Host Disease

China
Lee Dupuis
C17 Council

Completed

Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT

Acute-graft-versus-host Disease

Canada
Peking University People's Hospital
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China

Unknown

Human Amniotic Epithelial Cells Prevent Acute Graft-versus-host Disease After Hematopoietic Stem Cell Transplantation (hAECs-GVHD)

Acute-graft-versus-host Disease

China
Peking University People's Hospital

Unknown

Prophylaxis Roles of IL-2 Treatment on GVHD After Transplantation

Acute Graft-versus-host Disease

China
Jules Bordet Institute
Macopharma; Belgian Hematological Society

Recruiting

Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)

Refractory Chronic Graft Versus Host Disease (cGVHD)

Belgium
John Levine

Completed

Itacitinib for Low Risk GVHD

GVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-disease

United States
Equillium
Biocon Limited

Recruiting

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

Graft Versus Host Disease | GVHD | aGVHD | Acute-graft-versus-host Disease | Acute GVHD

United States, Korea, Republic of, Germany, Israel, Spain, Belgium, Italy, Australia, France, Canada, Portugal, New Zealand
Equillium
Biocon Limited

Recruiting

A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD (EQUATE)

GVHD | GVHD, Acute | aGVHD | Acute-graft-versus-host Disease

United States
Alexion Pharmaceuticals

Terminated

A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease (GIGVHD)

Acute Graft-Versus-Host Disease | GIGVHD

United States, France
MaaT Pharma

Recruiting

Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 (ORION)

Steroid Refractory GVHD | Intestinal GVHD

France

Clinical Trials on Steroid Refractory Acute Graft Versus Host Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations